Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002279 · ClinicalTrials.gov registry record · NA

A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)

A NA study of HIV Infections, sponsored by Hoffmann-La Roche.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002279: Completed NA study of HIV Infections, sponsored by Hoffmann-La Roche.

NCT00002279 is a NA study of HIV Infections that has completed, run by Hoffmann-La Roche. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002279, a NA study of HIV Infections, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

AMENDED: To provide ddC for patients with AIDS or advanced ARC who have failed treatment with, are intolerant to or are ineligible to receive zidovudine (AZT) and to demonstrate that ddC monotherapy is safe, and tolerable in this patient population. Original design: To provide zalcitabine (dideoxycytidine; ddC) for patients with AIDS or advanced AIDS-related complex (ARC) who have failed treatment with or are intolerant to zidovudine (AZT) and who are also intolerant to dideoxyinosine (ddI); to demonstrate that ddC monotherapy is safe and tolerable in the treatment of patients who previously experienced either treatment failure, hematologic intolerance or myositis with AZT treatment and pancreatitis or other toxicities (except peripheral neuropathy with ddI).

Conditions Studied

HIV Infections

Interventions

  • DRUG Zalcitabine

Study Locations (1)

New Jersey

  • Hoffmann - La Roche Inc - Nutley

Trial Details

FieldValue
Phase NA
Hoffmann-La Roche

909 total trials

What the finished NCT00002279 record still lists

NCT00002279 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Zalcitabine is the first listed.

NCT00002279 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002279 about?

NCT00002279 is a clinical study titled "A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)". AMENDED: To provide ddC for patients with AIDS or advanced ARC who have failed treatment with, are intolerant to or are ineligible to receive zidovudine (AZT) and to demonstrate that ddC monotherapy is safe, and tolerable in this patient population. Original design: To provide zalcitabine (dideoxyc...

What is the current status of trial NCT00002279?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002279 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002279?

The interventions under investigation include: Zalcitabine (DRUG).

Who is sponsoring clinical trial NCT00002279?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002279 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002279, the US trial registry maintained by the National Library of Medicine. NCT00002279 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.